Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
JW (Cayman) Therapeutics Co. Ltd (JWCTF)
Shanghai, CN
JW (Cayman) Therapeutics Co. Ltd is a biopharmaceutical entity currently in the clinical development phase, dedicated to the discovery, manufacturing, and commercialization of advanced cell-based immunotherapeutic solutions. Its core mission is to combat both hematological cancers (blood cancers) and various solid tumors. The company's innovative treatments encompass cell-derived immunotherapies, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies, which leverage a patient's own immune cells to target and eliminate cancerous cells. Leading its clinical efforts is Carteyva (relmacabtagene autoleucel), an anti-CD19 CAR-T therapeutic agent aimed at various forms of blood cancer. Beyond its flagship product, JW (Cayman) Therapeutics maintains a promising product pipeline. This includes JWCAR129, an autologous CAR-T therapy for treating multiple myeloma; JWATM204, a T-cell receptor (TCR) T-cell therapy candidate for hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell therapy that mimics T-cell receptors, specifically designed to target alpha-fetoprotein in HCC. Established in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -14.49% | -14.49% | -21.99% | -47.05% | -33.47% | -4.20% | -33.32% | -91.60% | -91.60% | -91.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+74.7% ★ Q4'25: +102.5% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+7.0% Q4'25: +27.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-41.6% Q4'25: -45.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-87.5% Q4'25: -102.4% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-76.5% Q4'25: -226.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.5% ★ Q4'25: +1.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.62× Q4'25: -0.47× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
30.80M
est: 94.62M (-67.5%)
|
145.70M
est: 148.58M (-1.9%)
|
173.86M
est: 183.85M (-5.4%)
|
158.22M
est: 183.27M (-13.7%)
|
276.33M
est: 243.65M (+13.4%)
|
322.10M
322.10M – 322.10M
+32.2% YoY
|
835.12M
835.12M – 835.12M
+159.3% YoY
|
| EBITDA |
-738.70M
est: -56.77M (-1,201.2%)
|
-752.27M
est: -89.15M (-743.8%)
|
-655.75M
est: -110.31M (-494.5%)
|
-488.74M
est: -168.10M (-190.7%)
|
-161.97M
est: -223.48M (+27.5%)
|
-295.44M
-295.44M – -295.44M
-32.2% YoY
|
-765.99M
-765.99M – -765.99M
-159.3% YoY
|
| EBIT |
-771.72M
est: -56.77M (-1,259.3%)
|
-839.35M
est: -89.15M (-841.5%)
|
-755.58M
est: -110.31M (-585.0%)
|
-578.40M
est: -178.68M (-223.7%)
|
-241.73M
est: -237.55M (-1.8%)
|
-314.03M
-314.03M – -314.03M
-32.2% YoY
|
-814.20M
-814.20M – -814.20M
-159.3% YoY
|
| Net Income |
-702.33M
est: -544.97M (-28.9%)
|
-846.14M
est: -617.02M (-37.1%)
|
-768.00M
est: -718.13M (-6.9%)
|
-590.62M
est: -731.52M (+19.3%)
|
-540.96M
est: -428.12M (-26.4%)
|
-330.12M
-330.12M – -330.12M
+22.9% YoY
|
-209.63M
-209.63M – -209.63M
+36.5% YoY
|
| SGA |
372.25M
est: 325.99M (+14.2%)
|
370.64M
est: 511.88M (-27.6%)
|
117.75M
est: 633.39M (-81.4%)
|
145.16M
est: 623.81M (-76.7%)
|
219.02M
est: 829.30M (-73.6%)
|
1.10B
1.10B – 1.10B
+32.2% YoY
|
2.84B
2.84B – 2.84B
+159.3% YoY
|
| EPS |
-1.76
est: -1.32 (-33.6%)
|
-2.06
est: -1.49 (-38.1%)
|
-1.87
est: -1.74 (-7.7%)
|
-1.43
est: -1.76 (+18.7%)
|
-1.33
est: -1.03 (-29.2%)
|
-0.79
-0.79 – -0.79
+22.9% YoY
|
-0.50
-0.50 – -0.50
+36.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yiping Li | Co-Founder & Director | 837.0K | — |
| Min Liu | Chief Executive Officer & Executive Chairman | 261.3K | male |
| Feng Tian | CEO & Executive Director | 5.0K | male |
| Mark J. Gilbert | Senior Advisor & Acting Chief Medical Officer | — | male |
| Chunan Chen | Senior Vice President | — | male |
| Zhen Xia | Head of Clinical Science Department | — | female |
| Jihua Qin | Vice President and Head of Marketing & Medical Affairs | — | female |
| Ka Man Ng | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JWCTF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
